HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis, and gemcitabine-based chemotherapy remains an effective option for the majority of PDAC patients. Hepatocyte nuclear factor 1α (HNF1A) is a tumor-suppressor in PDAC, but its role in gemcitabine chemores...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yanan, Xu, Dongni, Peng, Jintao, Luo, Zhaofan, Chen, Chujie, Chen, Yuqing, Chen, Huimou, Zheng, Minghui, Yin, Peihong, Wang, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606897/
https://www.ncbi.nlm.nih.gov/pubmed/31103629
http://dx.doi.org/10.1016/j.ebiom.2019.05.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606897/
https://www.ncbi.nlm.nih.gov/pubmed/31103629
http://dx.doi.org/10.1016/j.ebiom.2019.05.013

Ejemplares similares